- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04706364
Investigation of Brain Plasticity in Autism Spectrum Disorders
Investigations of Sensorimotor Plasticity in Autism Spectrum Disorders
Study Overview
Status
Conditions
Detailed Description
Individuals with autism spectrum disorders (ASD) commonly experience variances in tactile behaviors, such as hypersensitivity to light touch stimuli, altered texture discrimination and hyporesponsivity to pain. The degree of this somatosensory impairment correlates with increased anxiety behaviors as well as impairments in social behavior among ASD patients.
There remains an unmet need for suppressing the tactile hypersensitivity, which may improve anxiety and other core symptoms of ASD; however, methodologies for measuring tactile sensitivity vary widely across clinical and basic research fields. There is an urgent need for direct and objective sensory reactivity metrics in clinical studies to assess deficits in specific patient populations and for designing effective therapeutic strategies. As compared with traditional behavioral methods, the investigators propose to test novel, objective and quantitative metrics of somatosensory sensitivity in individuals with ASD.
In addition, transcranial magnetic stimulation (TMS) provides a method of measuring cortical reactivity offering the advantage of providing behaviorally independent results that are largely unaffected by attention or cognitive ability. Therefore, a TMS-based physiologic biomarker may be applicable to all individuals across the autism spectrum. A form of TMS known as paired associative stimulation (PAS) can be used to study the suggested impairment in integration of sensory input into cortical function that underlies tactile hypersensitivity in ASD. Thus, the investigators aim to investigate somatosensory sensitivity and sensorimotor integration utilizing novel, objective behavioral assays and TMS.
Participation in the study will consist of up to seven visits: one screening visit, two sensory testing visits, and two - four TMS sessions. The screening visit is expected to last between 2-3 hours, during which participants will first provide informed consent. Participants will then receive a thorough medical examination by a neurologist, and a neuropsychological evaluation (including IQ measures and ASD specific evaluations). If eligible to continue, participants will then come back for two sensory visits and two - four TMS visits that are spaced a minimum of 1 week apart.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Paul MacMullin
- Phone Number: 617-355-4875
- Email: Paul.MacMullin@childrens.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Contact:
- Paul MacMullin
- Phone Number: 617-355-4875
- Email: Paul.MacMullin@childrens.harvard.edu
-
Principal Investigator:
- Alexander Rotenberg, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
For ASD group:
Clinical diagnosis of a disorder on the autism spectrum according to:
- DSM-IV or DSM 5 criteria
- IQ>70 (as determined by the Abbreviated Stanford-Binet IQ)
For the Control group:
- No history of ASD or other developmental delay
- No history of ASD or other developmental delay in first-degree relatives.
- No history of clinical diagnosis of an anxiety disorder
Exclusion Criteria:
Both ASD and Control groups:
- Intracranial pathology, cerebral palsy, history of severe head injury, or syndromic dysmorphology
- History of fainting spells of unknown or undetermined etiology that might constitute seizure
- History of seizure or epilepsy
- Chronic (particularly) uncontrolled medical conditions that may cause a medical emergency
- Metal implants (excluding dental fillings) or devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt unless cleared by the responsible MD
- Substance abuse or dependence within the past six months
- Chronic treatment with prescription medications that decrease cortical seizure threshold
- Peripheral neuropathy, as determined by the study MD during neurologic exam
For the Control group:
- For control participants' medical history will be reviewed for diagnoses of neurologic or psychiatric disease. If in the judgment of the investigator, the condition, e.g., depression, is well-controlled with stable medications, and does not include abnormalities of the sensory motor systems, they may be included in the study. Control participants will be excluded from taking part in the study if they have a 1st degree relative with ASD.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Autism Spectrum Disorder (ASD)
Individuals diagnosed with an Autism Spectrum Disorder
|
Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes. Genetic testing is funded by Boston Children's Hospital. Three different tests will be completed: the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold). Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist). The second sensory visit will be another version of the PPI testing involving hearing and sound.
A cap will be placed on the participants head that will be filled with electrodes (small discs).
The EEG will allow investigators to measure how the brain reacts to the sensory testing.
Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex. There will be two - four identical TMS testing visits. |
Healthy Control
Typically developing individuals without a history of autism
|
Includes an IQ test, Autism Diagnostic Observation Schedule-2 (ADOS-2), and Autism Diagnostic Interview-Revised (ADI-R) assessments.
The sample is to test for genes (BDNF/APOE/COMT) that everyone has, but people have different varieties of these genes. Genetic testing is funded by Boston Children's Hospital. Three different tests will be completed: the tactile prepulse inhibition test (PPI) texture perception indentation testing (Mechanical Detection Threshold). Investigators will also apply mild electrical stimulation to the median nerve of the hand (on the wrist). The second sensory visit will be another version of the PPI testing involving hearing and sound.
A cap will be placed on the participants head that will be filled with electrodes (small discs).
The EEG will allow investigators to measure how the brain reacts to the sensory testing.
Single pulses of TMS, as well as PAS (a second type of TMS), will be applied to the cortex. There will be two - four identical TMS testing visits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Textured novel object recognition test (NORT) and mechanical detection threshold (MDT) with von Frey hairs
Time Frame: 3 years
|
To assess the validity of tactile prepulse inhibition (PPI) and other quantitative somatosensory assessments as potential biomarkers for somatosensory dysfunction in children with ASD.
These metrics will provide a valuable comparison to the more-quantitative physiological measures by PAS and PPI.
|
3 years
|
Somatosensory temporal discrimination threshold (STDT) and PAS-induced modulation of motor-evoked potentials (MEPs)
Time Frame: 3 years
|
To assess the validity of PAS-induced modulation of corticospinal excitability as a neurophysiologic biomarker for somatosensory dysfunction in children with ASD.
|
3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexander Rotenberg, MD, PhD, Alexander.Rotenberg@childrens.harvard.edu
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-P00027556
- R21MH120438 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Neuropsychological Testing
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Stanford UniversityWashington University School of Medicine; University of Wisconsin, MadisonCompletedCarotid Artery StenosisUnited States
-
University of South FloridaUnknown
-
University of South FloridaMayo Clinic; Florida Department of Health; Mt. Sinai Medical Center, MiamiUnknown
-
Hadassah Medical OrganizationWithdrawn
-
Ohio State UniversityBrain Test, Inc.Active, not recruitingDementia | Mild Cognitive ImpairmentUnited States
-
First Affiliated Hospital of Harbin Medical UniversityRecruitingCerebrovascular Disease Small VesselChina
-
Charite University, Berlin, GermanyNot yet recruiting
-
Stanford UniversityNot yet recruiting
-
Rehabilitation Hospital of IndianaNot yet recruitingNeuropsychology | Testing